Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
8.50 -0.66 (-7.21%) 11:51 ET [NASDAQ]
8.43 x 200 8.51 x 72
Realtime by (Cboe BZX)
8.43 x 200 8.51 x 72
Realtime 9.30 +0.14 (+1.53%) 08:42 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.50
Day High
8.90
Open 8.79
Previous Close 9.16 9.16
Volume 202,644 202,644
Avg Vol 1,454,842 1,454,842
Stochastic %K 12.20% 12.20%
Weighted Alpha -49.36 -49.36
5-Day Change -1.19 (-12.21%) -1.19 (-12.21%)
52-Week Range 3.73 - 19.18 3.73 - 19.18
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 495,345
  • Shares Outstanding, K 54,077
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -184 M
  • EBITDA $ -172 M
  • 60-Month Beta 0.42
  • Price/Sales 16.63
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 111.09% ( +40.99%)
  • Historical Volatility 111.99%
  • IV Percentile 81%
  • IV Rank 58.91%
  • IV High 180.71% on 07/03/24
  • IV Low 11.27% on 05/07/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 14
  • Volume Avg (30-Day) 1,128
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 34,164
  • Open Int (30-Day) 34,770

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.07
  • Number of Estimates 5
  • High Estimate -0.66
  • Low Estimate -1.48
  • Prior Year -1.36
  • Growth Rate Est. (year over year) +21.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.76 +10.31%
on 04/09/25
Period Open: 11.70
14.97 -42.82%
on 03/25/25
-3.14 (-26.84%)
since 03/10/25
3-Month
7.76 +10.31%
on 04/09/25
Period Open: 13.85
16.80 -49.05%
on 02/06/25
-5.29 (-38.19%)
since 01/10/25
52-Week
3.73 +129.49%
on 07/05/24
Period Open: 5.02
19.18 -55.37%
on 01/07/25
+3.54 (+70.52%)
since 04/10/24

Most Recent Stories

More News
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

QURE : 8.51 (-7.10%)
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

QURE : 8.51 (-7.10%)
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

QURE : 8.51 (-7.10%)
uniQure Announces Pricing of its Public Offering

QURE : 8.51 (-7.10%)
uniQure Announces Proposed Public Offering

QURE : 8.51 (-7.10%)
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's...

QURE : 8.51 (-7.10%)
uniQure Announces FDA Agreement on Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

The FDA supports uniQure's AMT-130 for Huntington's disease under an Accelerated Approval pathway using existing study data.Quiver AI SummaryuniQure N.V. announced that the U.S. Food and Drug Administration...

QURE : 8.51 (-7.10%)
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

QURE : 8.51 (-7.10%)
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

QURE : 8.51 (-7.10%)
uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...

QURE : 8.51 (-7.10%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 11.63
2nd Resistance Point 10.57
1st Resistance Point 9.87
Last Price 8.51
1st Support Level 8.11
2nd Support Level 7.05
3rd Support Level 6.35

See More

52-Week High 19.18
Fibonacci 61.8% 13.28
Fibonacci 50% 11.45
Fibonacci 38.2% 9.63
Last Price 8.51
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar